文献速递传染病防控与疫情报告免疫规划卫生政策与健康促进

建模显示基于疫苗的高效干预可消除芝加哥注射吸毒者中的丙肝

Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
PubMed 文献 · Vaccine · 2019-04-05

研究通过数学模型模拟芝加哥注射吸毒者(PWID)中丙肝病毒(HCV)的流行,比较疫苗接种、直接抗病毒药物(DAA)治疗及联合策略的成本与效果。结果显示,疫苗与DAA联合是达成WHO将HCV发病率降低90%目标成本最低的干预,也是15年内将患病率减半最经济的方式;单独使用DAA成本效果较差且存在再感染风险,单独接种疫苗无法在高流行人群实现90%发病率下降。

要点

  • 疫苗与DAA联合是达成HCV发病率降低90%目标最经济的策略。
  • 单独DAA治疗成本效果较差且存在治疗后再感染风险。
  • 单独接种疫苗即使覆盖所有可及PWID也无法在高流行人群实现90%发病率下降。

核心结论

  • 建模结果强调开发有效HCV疫苗并将疫苗与DAA联合用于HCV干预策略的重要性,以实现发病率和患病率的高效降低。

研究设计与样本

  • 研究建立代表PWID中HCV流行的数学模型,并校准至美国伊利诺伊州芝加哥大都市区的实证数据。
  • 模型考虑四种医疗干预:HCV阴性PWID接种疫苗、DAA治疗、DAA治疗后接种疫苗、疫苗与DAA联合。

主要发现

  • 疫苗与DAA联合是达成WHO将HCV发病率降低90%目标成本最低的干预。
  • 单独使用DAA而不接种疫苗成本效果远较差,且治疗后存在再感染额外风险。
  • 单独接种HCV阴性PWID疫苗即使扩大至所有可及PWID,在高流行人群也无法实现90%发病率下降,因接种前已发生感染。
  • 15年内将患病率减半成本最低的方式是疫苗与DAA联合。

关键数值与推荐

  • WHO提出将HCV发病率降低90%作为关键目标。
  • 研究报告口服直接抗病毒药物(DAA)治愈率>90%。
  • 研究目标为在PWID人群中通过疫苗与DAA双模式方法将HCV发病率降低90%、患病率降低50%。
  • 15年内将患病率减半的最经济方式为疫苗与DAA联合。

临床怎么用

  • 在PWID的HCV防控中,应优先考虑将疫苗与DAA联合的干预策略以高效降低发病率和患病率。
  • 单独依赖DAA治疗需关注再感染风险及成本效果较差的问题。
  • 单独接种疫苗不足以在高流行人群实现发病率大幅下降,需与治疗结合。

局限性

  • 研究为数学模型,校准基于芝加哥大都市区实证数据,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Persons who inject drugs (PWID) are at highest risk for acquiring and transmitting hepatitis C (HCV) infection. The recent availability of oral direct-acting antiviral (DAA) therapy with reported cure rates >90% can prevent HCV transmission, making HCV elimination an attainable goal among PWID. The World Health Organization (WHO) recently proposed a 90% reduction in HCV incidence as a key objective. However, given barriers to the use of DAAs in PWID, including cost, restricted access to DAAs, and risk of reinfection, combination strategies including the availability of effective vaccines are needed to eradicate HCV as a public health threat. This study aims to model the cost and efficacy of a dual modality approach using HCV vaccines combined with DAAs to reduce HCV incidence by 90% and prevalence by 50% in PWID populations. METHODS: We developed a mathematical model that represents the HCV epidemic among PWID and calibrated it to empirical data from metropolitan Chicago, Illinois. Four medical interventions were considered: vaccination of HCV naive PWID, DAA treatment, DAA treatment followed by vaccination, and, a combination of vaccination and DAA treatment. RESULTS: The combination of vaccination and DAAs is the lowest cost-expensive intervention for achieving the WHO target of 90% incidence reduction. The use of DAAs without a vaccine is much less cost-effective with the additional risk of reinfection after treatment. Vaccination of naïve PWID alone, even when scaled-up to all reachable PWID, cannot achieve 90% reduction of incidence in high-prevalence populations due to infections occurring before vaccination. Similarly, the lowest cost-expensive way to halve prevalence in 15 years is through the combination of vaccination and DAAs. CONCLUSIONS: The modeling results underscore the importance of developing an effective HCV vaccine and augmenting DAAs with vaccines in HCV intervention strategies in order to achieve efficient reductions in incidence and prevalence.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Echevarria D, Gutfraind A, Boodram B, et al. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago. Vaccine. 2019. PMID: 30962092. doi:10.1016/j.vaccine.2019.02.081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。